Patent Issued for Bridged tricyclic carbamoylpyridone compounds and uses thereof (USPTO 12024528).

A patent has been issued to Gilead Sciences Inc. for bridged tricyclic carbamoylpyridone compounds and their uses in treating HIV infections. The compounds have antiviral activity and may be effective against drug-resistant HIV variants. They also have a decreased potential for drug interactions and can be administered with less than daily frequency. The patent includes claims for the compounds, pharmaceutical compositions containing them, kits, and methods of treating HIV infections. This information is important for researchers studying antiretroviral therapies and the development of new drugs to combat HIV. [Extracted from the article]